FOMX Foamix Pharmaceuticals Ltd.

3.66
+0.12  (+3%)
Previous Close 3.54
Open 3.52
Price To Book 3.7
Market Cap 223,274,373
Shares 61,003,927
Volume 174,451
Short Ratio
Av. Daily Volume 818,121

NewsSee all news

  1. Foamix Announces Enrollment of First Patient in Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam

    REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), today announced that the first patient has been enrolled in its Phase 2 clinical trial to evaluate

  2. Foamix Announces Issuance of New U.S. Patent Covering A Method of Treating Acne that Expires in 2037

    REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a clinical stage specialty pharmaceutical company focused on developing

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

NDA filing announced August 5, 2019.
FMX103
Papulopustular rosacea
PDUFA date October 20, 2019.
FMX101
Acne
Phase 2 data released December 2015
FDX104
Acne-like rash in cancer patients
Update to be provided as it materializes.
FDX102
Impetigo

Latest News

  1. Foamix Announces Enrollment of First Patient in Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam

    REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), today announced that the first patient has been enrolled in its Phase 2 clinical trial to evaluate

  2. Foamix Announces Issuance of New U.S. Patent Covering A Method of Treating Acne that Expires in 2037

    REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a clinical stage specialty pharmaceutical company focused on developing